Replimune Group, Inc. (NASDAQ:REPL) Shares Bought by Jane Street Group LLC

Jane Street Group LLC lifted its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 20.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 316,287 shares of the company's stock after purchasing an additional 54,039 shares during the quarter. Jane Street Group LLC owned about 0.46% of Replimune Group worth $3,830,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of REPL. Sterling Capital Management LLC lifted its position in Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after buying an additional 1,655 shares in the last quarter. MetLife Investment Management LLC raised its stake in shares of Replimune Group by 7.2% in the 4th quarter. MetLife Investment Management LLC now owns 37,659 shares of the company's stock valued at $456,000 after acquiring an additional 2,525 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Replimune Group by 24.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company's stock valued at $198,000 after acquiring an additional 3,177 shares in the last quarter. SG Americas Securities LLC boosted its position in Replimune Group by 14.7% during the 4th quarter. SG Americas Securities LLC now owns 26,291 shares of the company's stock worth $318,000 after purchasing an additional 3,374 shares during the period. Finally, Tower Research Capital LLC TRC boosted its position in Replimune Group by 696.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock worth $82,000 after purchasing an additional 5,922 shares during the period. Institutional investors and hedge funds own 92.53% of the company's stock.

Analysts Set New Price Targets

REPL has been the topic of several analyst reports. JPMorgan Chase & Co. raised their target price on Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. BMO Capital Markets increased their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright boosted their target price on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $19.43.

Replimune Group Stock Up 10.7%

REPL traded up $0.77 on Friday, reaching $8.00. The company's stock had a trading volume of 700,771 shares, compared to its average volume of 900,971. Replimune Group, Inc. has a 1 year low of $4.92 and a 1 year high of $17.00. The business's 50 day moving average is $9.02 and its 200 day moving average is $11.36. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. The stock has a market cap of $616.12 million, a price-to-earnings ratio of -2.63 and a beta of 0.68.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). As a group, research analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.